Suppr超能文献

绿茶多酚的分子机制。

Molecular mechanisms of green tea polyphenols.

机构信息

Barbara Ann Karmanos Cancer Institute, Department of Pathology, School of Medicine, Wayne State University, Detroit, Michigan 48201, USA.

出版信息

Nutr Cancer. 2009;61(6):827-35. doi: 10.1080/01635580903285049.

Abstract

Tea, next to water, is the most popular beverage in the world. It has been suggested that tea consumption has the cancer-preventive effects. Epidemiological studies have indicated decreased cancer occurrence in people who regularly drink green tea. Research has also discovered numerous mechanisms of action to explain the biological effects of tea. The most abundant and popular compound studied in tea research is (-)-epigallocatechin-3-gallate or (-)-EGCG, which is a powerful antioxidant and can inhibit a number of tumor cell proliferation and survival pathways. Tea polyphenols are known to inhibit metaloproteonases, various protein kinases, and proteins that regulate DNA replication and transformation. We also reported that ester bond-containing tea polyphenols, for example, (-)-EGCG, potently and specifically inhibited the tumor proteasomal activity. We further demonstrated that methylation on green tea polyphenols under physiological conditions decreased their proteasome-inhibitory activity, contributing to decreased cancer-preventive effects of tea consumption. Since (-)-EGCG is unstable under physiological conditions, we also developed the peracetate-protected or prodrug form of (-)-EGCG, Pro-EGCG (1), and showed that Pro-EGCG (1) increases the bioavailability, stability, and proteasome-inhibitory and anticancer activities of (-)-EGCG in human breast cancer cells and tumors, demonstrating its potential use for cancer prevention and treatment.

摘要

茶是世界上除水之外最受欢迎的饮料。有研究表明,饮茶具有防癌作用。流行病学研究表明,经常饮用绿茶的人群癌症发病率较低。研究还发现了许多作用机制来解释茶的生物学效应。在茶的研究中,研究最多、最广泛的化合物是(-)-表没食子儿茶素-3-没食子酸酯((-)-EGCG),它是一种强大的抗氧化剂,可以抑制许多肿瘤细胞的增殖和存活途径。茶多酚可以抑制金属蛋白酶、多种蛋白激酶以及调节 DNA 复制和转化的蛋白质。我们还报告说,酯键含有的茶多酚,例如(-)-EGCG,能够强烈且特异性地抑制肿瘤蛋白酶体的活性。我们进一步证明,在生理条件下,绿茶多酚上的甲基化会降低其对蛋白酶体的抑制活性,从而降低茶的防癌效果。由于(-)-EGCG 在生理条件下不稳定,我们还开发了(-)-EGCG 的醋酸酯保护或前药形式,Pro-EGCG(1),并表明 Pro-EGCG(1)增加了(-)-EGCG 在人乳腺癌细胞和肿瘤中的生物利用度、稳定性、蛋白酶体抑制和抗癌活性,显示出其在癌症预防和治疗方面的潜在用途。

相似文献

1
Molecular mechanisms of green tea polyphenols.
Nutr Cancer. 2009;61(6):827-35. doi: 10.1080/01635580903285049.
2
Methylation suppresses the proteasome-inhibitory function of green tea polyphenols.
J Cell Physiol. 2007 Oct;213(1):252-60. doi: 10.1002/jcp.21124.
3
Green tea polyphenols as a natural tumour cell proteasome inhibitor.
Inflammopharmacology. 2008 Oct;16(5):208-12. doi: 10.1007/s10787-008-8017-8.
7
The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention.
Arch Biochem Biophys. 2010 Sep 1;501(1):65-72. doi: 10.1016/j.abb.2010.06.013. Epub 2010 Jun 15.
10
Green tea polyphenols as proteasome inhibitors: implication in chemoprevention.
Curr Cancer Drug Targets. 2011 Mar;11(3):296-306. doi: 10.2174/156800911794519743.

引用本文的文献

3
Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression.
Curr Genomics. 2017 Apr;18(2):175-205. doi: 10.2174/1389202917666160803165229.
4
Therapeutic properties of green tea against environmental insults.
J Nutr Biochem. 2017 Feb;40:1-13. doi: 10.1016/j.jnutbio.2016.05.005. Epub 2016 May 27.
9
Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea.
J Nutr Biochem. 2014 Jan;25(1):73-80. doi: 10.1016/j.jnutbio.2013.09.005. Epub 2013 Oct 10.
10
Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy.
Genet Res Int. 2013;2013:852080. doi: 10.1155/2013/852080. Epub 2013 Feb 19.

本文引用的文献

1
A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
Cancer Res. 2007 May 1;67(9):4303-10. doi: 10.1158/0008-5472.CAN-06-4699.
2
Methylation suppresses the proteasome-inhibitory function of green tea polyphenols.
J Cell Physiol. 2007 Oct;213(1):252-60. doi: 10.1002/jcp.21124.
4
Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Drug Resist Updat. 2005 Aug;8(4):205-18. doi: 10.1016/j.drup.2005.06.001. Epub 2005 Jul 12.
5
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445.
8
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
J Clin Oncol. 2005 Feb 1;23(4):667-75. doi: 10.1200/JCO.2005.03.108. Epub 2004 Dec 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验